Australia approves health registration for new cannabis inhalation device
The liquid cannabis inhalation device is registered in Australia. Understand how the QMID works and what changes for patients.
The Australian health authority, the Therapeutic Goods Administration (TGA), included the Que Medical Inhalation Device (QMID), developed to administer liquid medicinal cannabis extracts via inhalation, in the Australian Register of Therapeutic Goods (ARTG) on September 15, 2026. The information was reported by the Spanish portal Cáñamo and announced by Curaleaf International in October.
READ MORE: Cannabis vaporizer market expected to jump to US$ 17.11 billion by 2032
The device was developed in partnership with Jupiter Research and uses compatible cartridges to produce an inhalable aerosol. The approach differs from devices intended for the vaporization of cannabis flower by focusing on liquid formulations.
Inclusion in the health registry distinguishes the regulation of the equipment from the authorization of the medications used with it. The registration, in itself, does not demonstrate that the device is more effective or safer than other administration methods.
READ MORE: The urgency of regulating cannabis vaporizers in Brazil: between institutional omission and the right to health
The published information regarding the QMID does not present sufficient comparative data to establish clinical superiority or confirm specific benefits for patients. The evaluation of such technologies depends on evidence regarding safety, dosage, performance, and conditions of use.
In Australia, the availability of both the device and the extracts used is subject to their respective regulatory requirements. Listing the equipment does not imply that any cannabis formulation can be used with it, nor that all associated medications are automatically authorized.
The registration adds an option to the range of technologies intended for administering medical cannabis in the country. The clinical impact of the new device will depend on applicable indications, access conditions, and available scientific evidence.